pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 8·1 min read
save

FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering

🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said. The agency asked for more information from ...

May 8, 2026·read at Endpoints ↗

May 8, 2026 11:09 AM EDT News Briefing FDA de­lays Leqem­bi de­ci­sion; Arti­va rais­es $300M on RA da­ta; Phar­varis prices of­fer­ing ENDPOINTS 🗓️ FDA de­lays sub­cu­ta­neous Leqem­bi de­ci­sion: Orig­i­nal­ly slat­ed for lat­er this month, the de­ci­sion date now falls on Au­gust 24, Bio­gen and Ei­sai Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
79 words · retrieved May 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Sionna Therapeutics, Inc.3
drugs
LEQEMBI2lecanemab2

related stories

  • Jul 30Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storeBioSpace
  • Jul 29Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology pushBioPharma Dive
  • Jul 29Leqembi records best quarter since launch as Biogen raises underlying guidanceEndpoints
  • Jul 23Biogen counts on drugs from Apellis deal to patch Leqembi's slow salesEndpoints
  • Jul 14Erasca's $550M offering; Summit sells an antibioticEndpoints